Soft tissue sarcoma

Disease Description (Causes and Symptoms)

• Definition: Soft tissue sarcoma is a general term for malignant tumors originating in soft tissues such as muscles, connective tissue, blood vessels, lymphatic vessels, and fat. It is rare, accounting for approximately 1% of adult malignant tumors, and there are more than 50–60 tissue subtypes.
• Causes/Pathophysiology: In most cases, the exact disease mechanism or genetic risk factors have not been identified. Some subtypes may be associated with radiation exposure or hereditary tumor syndromes (e.g., Li-Fraumeni syndrome). Histopathological differentiation (grade) and the tumor’s size, depth, and resectability have a major impact on prognosis.
• Main symptoms: The most common presentation is a usually asymptomatic, slowly growing lump (a painless mass that can be felt). When it develops in a deep location (the abdominal or thoracic cavity), it often remains asymptomatic until it becomes quite large. Sarcomas of the limbs tend to metastasize to the lungs, while retroperitoneal sarcomas (behind the abdominal cavity) frequently metastasize to the liver and within the abdominal cavity and show local invasion. Lymph node involvement at diagnosis is relatively uncommon (<10%).

Treatment Methods

• Treatment goals: When possible, seek a cure through complete surgical resection with negative margins. If the tumor is unresectable or has distant metastases, systemic treatment is used to prolong life and relieve symptoms.
• Surgery: Wide excision is the standard. If the margins are inadequate, repeat surgery may be considered. For tumors occurring in a limb, limb-sparing surgery is considered first if function can be preserved (with a prosthesis or reconstruction if necessary). Amputation may be necessary when major nerves or blood vessels are extensively involved or functional recovery is impossible.
• Radiation therapy (RT): Used as an adjunct before surgery (to reduce the tumor and improve resectability) or after surgery (to control residual microscopic disease). It is generally recommended for high-risk cases (>5 cm, high grade, inadequate margins, etc.). A typical schedule: preoperative RT begins about 3 weeks before surgery, and postoperative RT begins after wound healing (approximately 10–20 days). External-beam radiation is typically administered for 5–7 weeks.
• Chemotherapy (systemic treatment):
  • First-line treatment for metastatic/unresectable disease: Regimens such as doxorubicin ± ifosfamide are frequently used as standard treatment. The typical response rate is 15–35% (varies by subtype and report). When initiating treatment, the risks of myelosuppression, nausea/vomiting, hair loss, and cardiotoxicity (approximately 10%) should be considered.
  • Examples of subtype-specific targeted/subsequent therapies: imatinib for GIST; pazopanib for advanced non-adipocytic soft tissue sarcomas; and trabectedin or eribulin for some liposarcomas (depending on the subtype and clinical status).
• Other: Because some subtypes (e.g., target gene mutations associated with the sarcoma component) may qualify for targeted therapy or immunotherapy, molecular testing should be considered.
• Lifestyle management/Precautions:
  • A biopsy should be performed in accordance with the future surgical plan (the needle tract should be planned so that it can be removed during surgery)—an incorrectly located or performed biopsy may enlarge the extent of surgery because of tumor spread.
  • Chemotherapy and radiation therapy may cause side effects such as hair loss, nausea, risk of infection, and delayed wound healing, so regular blood tests and cardiac function assessments are necessary (when doxorubicin is used).
  • Wound care and rehabilitation (physical therapy) after surgery are important.

Checklist Before an Outpatient Visit (Including Example Questions)

• Items/medical records to prepare
  • List of medications currently being taken (including anticoagulants and supplements)
  • Medical history (especially previous radiation therapy, hereditary cancer syndromes, and heart disease)
  • Original copies or CDs of recently performed imaging studies (CT, MRI, PET) and the radiology reports
  • Results of previous biopsies (pathology reports) and slides (if possible)
  • Record of symptom changes: changes in mass size, presence or absence of pain, shortness of breath, weight changes, etc.
  • Allergies and pregnancy status (for women)
• Items to check during the outpatient visit (self-check)
  • Growth rate of the mass (changes over the past few weeks/months)
  • Pain and functional impairment (limited movement, neurological symptoms)
  • Respiratory symptoms (if pulmonary metastasis is suspected)
• Example questions (to prepare before the appointment)
  • What is the histological subtype and grade of the current lesion?
  • Can it be completely removed surgically? What is the likelihood of limb preservation?
  • Is radiation therapy or chemotherapy needed before or after surgery?
  • What are the major side effects of chemotherapy, and what preventive measures are available?

Examples of General Questions to Ask the Doctor

• What is the histological subtype (and grade) of this cancer, and what does it mean for the prognosis?
• What is the recommended standard treatment pathway for this stage (the order and purpose of surgery, radiation, and chemotherapy)?
• Can complete surgical resection be expected, and if this is uncertain, what is the risk of recurrence or metastasis?
• What will follow-up testing involve after treatment (frequency and testing methods)?
• What are the major side effects of the chemotherapy drugs, and what is the plan for monitoring organ toxicity, including cardiac and neurological toxicity?

Examples of Disease-Specific Questions

• "What is the tissue subtype specified in the pathology report (e.g., liposarcoma, Ewing sarcoma, rhabdomyosarcoma, etc.)? Is molecular testing for MDM2 amplification or KIT/PDGFRA mutations necessary?"
• "Considering the location and size of this tumor, can negative surgical margins be secured? Is preoperative radiation or chemotherapy (neoadjuvant therapy) recommended to enable limb-sparing surgery?"
• (Additional) For women or men of reproductive age: "What effects will treatment have on fertility, and should fertility preservation (sperm, egg, or ovary preservation) be considered?"

Additional guidance: Treatment decisions are made by integrating the tissue subtype, stage (size, depth, and presence or absence of metastasis), the patient’s overall condition, and the patient’s preferences. In many cases, a multidisciplinary team (sarcoma board) can develop a more appropriate plan in terms of prognosis and preservation of function. If necessary, consider referral to a specialized soft tissue sarcoma treatment center with a multidisciplinary team.